---
title: "WuXi Biologics and Vertex Pharma have reached a licensing and research service agreement for innovative tri-specific TCE"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274742675.md"
description: "WuXi Biologics and Vertex Pharma signed a licensing and research service agreement regarding the innovative trispecific T cell engagers (TCE). Vertex Pharma will obtain the global exclusive development and commercialization rights for the TCE, while WuXi Biologics will receive an upfront payment as well as subsequent milestone payments and sales royalties, and will provide integrated contract research and development services"
datetime: "2026-02-04T01:58:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274742675.md)
  - [en](https://longbridge.com/en/news/274742675.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274742675.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274742675.md) | [English](https://longbridge.com/en/news/274742675.md)


# WuXi Biologics and Vertex Pharma have reached a licensing and research service agreement for innovative tri-specific TCE

WuXi Biologics (02269.HK) announced that it has signed a licensing and research service agreement with Vertex Pharma (VRTX.US) for an "innovative trispecific T cell engager" (TCE). Vertex Pharma plans to use it for the treatment of B cell-mediated autoimmune diseases.

According to the terms of the agreement, Vertex Pharma will receive global exclusive development and commercialization rights for the trispecific TCE, which is in the preclinical stage and aims to treat B cell-mediated autoimmune diseases. WuXi Biologics will receive an upfront payment and is eligible for milestone payments related to development, registration, and sales, as well as sales commissions after the product is launched.

In addition, WuXi Biologics will provide integrated contract research and development services for its innovative TCE

### 相關股票

- [Vertex Pharma (VRTX.US)](https://longbridge.com/zh-HK/quote/VRTX.US.md)
- [WUXI BIO (02269.HK)](https://longbridge.com/zh-HK/quote/02269.HK.md)

## 相關資訊與研究

- [Alphamab Oncology Starts First-in-Human Trial of Novel Bispecific ADC JSKN027](https://longbridge.com/zh-HK/news/279270151.md)
- [07:01 ETKali Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of KT501 for Rheumatoid Arthritis](https://longbridge.com/zh-HK/news/279582933.md)
- [Vertex Pharmaceuticals EVP and CMO Carmen Bozic Sells Shares](https://longbridge.com/zh-HK/news/279484414.md)
- [GEN secures BEBO Foundation approval for Phase II PD trial](https://longbridge.com/zh-HK/news/279413854.md)
- [Livforsakringsbolaget Skandia Omsesidigt Has $31.89 Million Stock Holdings in AbbVie Inc. $ABBV](https://longbridge.com/zh-HK/news/279566469.md)